RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea

FREDERICK, Md., Dec 3 (Bernama-GLOBE NEWSWIRE) — RoosterBio, Inc, a leading supplier of innovative cellular therapy bioprocess tools and scalable manufacturing solutions for regenerative medicine, today announced it entered into an exclusive agency agreement with Sartorius Korea Biotech, a subsidiary of the Sartorius Group, a leading international partner of the biopharmaceutical and life science research sectors. This strategic partnership combines Sartorius’ proven expertise in providing high-caliber bioprocess testing, technical and customer services to the local South Korean market, as well as its global reach, and RoosterBio’s advanced platform of RUO and cGMP-grade human mesenchymal stem/stromal cell (hMSC) working cell banks, optimized paired media, and hMSC bioprocess systems. This winning combination sets the stage for accelerating the development of new, effective medical treatments and expands RoosterBio’s footprint into Asia, especially in South Korea.

http://mrem.bernama.com/viewsm.php?idm=38847